ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 134 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.20 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,846,884 | -19.7% | 540,722 | +12.9% | 0.00% | -33.3% |
| Q2 2023 | $13,507,033 | +84.0% | 478,803 | +12.2% | 0.00% | +200.0% |
| Q1 2023 | $7,342,180 | -13.2% | 426,871 | +1.6% | 0.00% | -50.0% |
| Q4 2022 | $8,459,686 | -6.3% | 420,044 | +0.7% | 0.00% | 0.0% |
| Q3 2022 | $9,033,000 | -14.0% | 417,042 | +11.5% | 0.00% | 0.0% |
| Q2 2022 | $10,506,000 | -32.9% | 373,900 | +10.2% | 0.00% | -33.3% |
| Q1 2022 | $15,652,000 | -46.8% | 339,231 | -3.0% | 0.00% | -40.0% |
| Q4 2021 | $29,401,000 | +26.7% | 349,765 | +0.4% | 0.01% | +25.0% |
| Q3 2021 | $23,213,000 | +42.0% | 348,332 | +13.3% | 0.00% | +33.3% |
| Q2 2021 | $16,351,000 | +33.0% | 307,330 | +8.5% | 0.00% | +50.0% |
| Q1 2021 | $12,293,000 | -16.2% | 283,323 | +0.3% | 0.00% | -33.3% |
| Q4 2020 | $14,670,000 | +211.9% | 282,442 | +96.3% | 0.00% | +200.0% |
| Q3 2020 | $4,704,000 | -26.1% | 143,892 | +8.6% | 0.00% | -50.0% |
| Q2 2020 | $6,364,000 | – | 132,536 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,426,095 | $111,940,000 | 6.63% |
| Paradigm Biocapital Advisors LP | 287,577 | $13,269,000 | 3.51% |
| Avidity Partners Management LP | 3,176,999 | $146,587,000 | 3.05% |
| Integral Health Asset Management, LLC | 215,000 | $9,920,000 | 2.58% |
| Matrix Capital Management Company, LP | 4,349,279 | $200,676,000 | 2.41% |
| Affinity Asset Advisors, LLC | 207,500 | $9,574,000 | 1.53% |
| Ikarian Capital, LLC | 202,203 | $9,329,000 | 1.23% |
| Ghost Tree Capital, LLC | 80,000 | $3,691,000 | 0.80% |
| Eventide Asset Management | 761,000 | $35,113,000 | 0.55% |
| Perceptive Advisors | 501,509 | $23,140,000 | 0.46% |